Home  »  Ipo Review  »  Mankind Pharma Ipo

One of the largest pharmaceutical companies in India, Mankind Pharma, is coming up with an IPO consisting of an Offer for Sale. As per the sources, the company will be raising funds aggregating to Rs. 5000 – Rs. 5500 crores through the IPO.

Mankind Pharma IPO is offering 40,058,844 Equity Shares to be sold by the promoters and investor-selling shareholders. These shareholders will be offloading different proportions of their holding in the IPO.

Through Mankind Pharma IPO Review, we will be understanding the value and potential of this IPO.

Face Value Rs 1
Price Band Rs.1026 to Rs.1080 
Listing At BSE, NSE
Min. Order Quantity 13 Shares
Listing Date May 8, 2023
Offer for Sale Rs. 4,326.36 Crore
Fresh Issue Rs. NA Crore
IPO Size Rs. 4,326.36 Crore
Tick Size 1


Mankind Pharma IPO Overview

Mankind Pharma IPOThe fourth largest drug-making company in the domestic market, Mankind Pharma, is newly flooring its equity shares on the stock exchanges. The company has filed the Draft papers with the capital market regulator and will proceed with the IPO launch soon after the IPO is approved.

The Mankind Pharma IPO has already made a whoop as one of India’s largest IPO in the pharma industry.

Mankind Pharma IPO Important Dates

Events Date
IPO Opening Date Apr 25, 2023
IPO Closing Date Apr 27, 2023
Basis of Allotment Finalization May 3, 2023
Refunds Initiation May 4, 2023
Credit of Shares to Demat Account May 5, 2023
Share Listing Date May 8, 2023

Mankind Pharma IPO Dates are Apr 25, 2023, and Apr 27, 2023. The company filed the preliminary documents recently and will be heading forward after obtaining the SEBI.

Mankind Pharma is among the top pharma companies in India. It is a well-established group and the founder of various brands within. The IPO will be one of the largest IPOs in the pharma segment.

Mankind Pharma IPO Price, Size, Share Offerings

Face Value Rs.1
Price Band Rs.1026 to Rs.1080 
Offer for Sale Rs. 4,326.36 Crore
Fresh Issue Rs. NA Crore
IPO Size Rs. 4,326.36 Crore

Mankind Pharma IPO Size consists of 40,058,844 Equity Shares to be issued by way of an Offer for Sale. There will be no fresh issue of shares, and the existing shares will be transferred to new holders from the existing ones.

The IPO is a Book Built Issue, and the Mankind Pharma IPO Price will be determined through the Book Building Process. The face value of the equity shares is Rs. 1 each.

In consultation with the Book Running Lead Managers, the company and the selling shareholders will determine the issue price band and lot size for the subscription of shares.

Mankind Pharma IPO Grey Market Premium

Date GMP (Rs.) Kostak Rate (Rs.) Subject to Sauda (Rs.)
05 May 2023 Rs 100 Rs 300 Rs 800
04 May 2023 Rs 80 Rs 300 Rs 800
03 May 2023 Rs 80 Rs 300 Rs 800
02 May 2023 Rs 80 Rs 300 Rs 800
28 Apr 2023 Rs 30 Rs 250 Rs 500
27 Apr 2023 Rs 40 Rs 500 Rs 750
26 Apr 2023 Rs 70 Rs 500 Rs 750
25 Apr 2023 Rs 70 Rs 500 Rs 750
24 Apr 2023 Rs 90 Rs 500 Rs 1000

It will be interesting to see how the Grey Market reacts to the Mankind Pharma IPO and where its GMP will stand. The company will test the demand for its shares in the Grey Market. The premium price at which the shares are traded in this market is known as the Grey Market Premium.

Mankind Pharma IPO GMP will impact the price levels at which the investors bid during the subscription process.

Mankind Pharma IPO Subscription Status

Day / Date QIB NII RII Total Subscription
1st Day – 25th Apr 0.08x 0.33x 0.11x 0.15x
2nd Day – 26th Apr 1.86x 1.02x 0.25x 0.88x
3rd Day – 27th Apr 49.16x 3.80x 0.92x 15.32x
Shares Offered or Net Issue 8,011,769 6,008,827 14,020,596 28,041,192

Subscription is the opening of an IPO where the investors can apply and bid for the number of shares they wish to acquire. Since the price of the shares is not determined, investors place their bids at different prices.

Mankind Pharma IPO Subscription will remain open for a minimum of 3 working days. The category of investors is divided into the following three categories – Qualified Institutional Buyers, Non-Institutional Buyers, and Retail Buyers. The proportions of these investors will be different for the allocation of shares.

Mankind Pharma IPO Allotment Status

Once the IPO is closed, and the company has received all the bids from the public, it is time to determine the final listing price of the equity shares. After the price is decided, Mankind Pharma IPO Allotment will be made to the investors whose applications have been accepted by the issuer company.

The shares are then credited to the Demat accounts of the bidders.

Mankind Pharma IPO Live Performance

Mankind Pharma IPO Price can be checked from here. Investors are always eager about the latest price as they can accordingly plan their investment in the company’s shares they like.

Subscribe to Mankind Pharma IPO – Open Free Demat Account Now!

    Fill Your Details Here
    1. Open Demat AccountInvest in IPO

    Mankind Pharma – Company Review

    The journey of Mankind Pharma was embarked on in July 1991 in the form of a private company. In 2005, the company took a new leap and emerged as a public company, and subsequently, its name was changed to “Mankind Pharma Limited.” The company has not changed its name since then.

    The company has had a long journey over all these years. They have brought over 36 brands into the market, which acts as an aid for different situations. Some of the flagship brands of this company are Manforce condoms, Prega News, and Gas-O-Fast.

    Mankind Pharma operates and manufactures its drugs from its 23 Manufacturing facilities located in different parts.

    Products or Services

    Mankind Pharma stands largely on its three pillars, Quality, Affordability, and Accessibility. For decades now, the company has been driven towards thorough research and development and helping the world with its pharmaceutical products.

    The company has various brands to exist, and they have successfully created a niche for itself. Some of the popular brands of this company are Manforce, Moxikind-CV, Amlokind-AT, Gudcef, Nurokind-Gold, Cefakind, Telmikind, Unwanted-72, Dydroboon, Prega News, Codistar, Monticope, and many other.

    We are using and prefer one or the other product of their brands. Their quality assurance checks and efficient delivery have hiked their growth so much.

    Promoters and Holding

    The Promoters of Mankind Pharma Limited are:

    1. Ramesh Juneja
    2. Rajeev Juneja
    3. Sheetal Arora
    4. Ramesh Juneja Family Trust
    5. Rajeev Juneja Family Trust
    6. Prem Sheetal Family Trust

    The management of the company is built with highly experienced and competent individuals. Let’s find out about this team:

    1. Ramesh Juneja, in the position of Chairman and Whole-Time Director
    2. Rajeev Juneja, in the position of Vice-Chairman and Managing Director
    3. Sheetal Arora, in the position of Chief Executive Officer and Whole-Time Director
    4. Satish Kumar Sharma, in the position of Whole-Time Director
    5. Leonard Lee Kim, in the position of Non-Executive Director
    6. Surendra Lunia, in the position of Independent Director
    7. Tilokchand Punamchand Ostwal, in the position of Independent Director
    8. Bharat Anand, in the position of Independent Director
    9. Vivek Kalra, in the position of Independent Director
    10. Vijaya Sampath, in the position of Independent Director
    11. Arjun Juneja, in the position of Chief Operating Officer
    12. Anil Kumar, in the position of Chief Scientific Officer (Research Centre)
    13. Ashutosh Dhawan, in the position of Chief Financial Officer
    14. Pramod Gokhale, in the position of Chief Information Officer
    15. Pradeep Chugh, in the position of Company Secretary and Compliance Officer

    Is Mankind Pharma Good for Investment?

    Mankind Pharma Limited is a trusted group and has been delivering quality products to customers. They have captured a significant portion of the Indian market with some of their brands. The company employs over 14000 employees on its team.

    Mankind Pharma is the fourth largest pharma company in India, and its operations are growing continuously with time.

    As per sources, over 80% of doctors in the country have prescribed the formulation of Mankind Pharma in 2022. In recent years, the company has started focusing on chronic therapies and is making efforts to offer assistance.

    Mankind Pharma Financial Statements

    Amount (in INR & Million)
    31-Mar-22 31-Mar-21 Mar-20
    Assets 91,477.40 63,726.32 50,732.85
    Revenue 79,775.84 63,853.80 59,756.54
    Expense 60,174.33 47,054.46 45,494.54
    Profit After Tax 14,529.56 12,930.34 10,561.48

    Mankind Pharma is a strong company in terms of financial position as well. The company has whopping income statistics for recent years.

    The above table contains details related to the company’s total assets, total income, total expenses, and Profit after tax.

    The company posted a total income of Rs. 79,775.84 million for the financial year 2022. This income includes consolidated Revenue from operations and other income. The net profit of Mankind for the same period is Rs. 14,529.56 million, respectively..

    Earnings per Equity Share (in Million)
    31-Mar-22 31-Mar-21 Mar-20
    Basic & Diluted 35.78 31.59 25.72

    The company is making good luck for the investors as well. The EPS of Mankind Pharma stood at Rs. 35.78 as of March 2022. The EPS shows a positive lift from the last year.

    Mankind Pharma IPO Review

    Mankind Pharma IPO is purely an Offer for Sale for 40,058,844 equity shares by the promoters and Investor Selling Shareholders of the company.

    This includes the three promoters of the company, namely, Ramesh Juneja, Rajeev Juneja, and Sheetal Arora. The remaining investors offloading their shares are Cairnhill CIPEF Limited, Cairnhill CGPE Limited, Beige Limited, and Link Investment Trust.

    The proceeds of the IPO will be received by the selling shareholders. The company has proposed this IPO to execute the sale of the equity shares and to attain the advantages of listing shares on the stock exchanges.

    Mankind Pharma IPO Details

    Here are a few more details you need to know before investing in Mankind Pharma IPO –

    Mankind Pharma IPO Issue Object

    Thus Mankind Pharma has proposed diverse objectives for making the IPO offer and some of the objectives are:

    • Carry out the Offer for Sale of 40,058,844 Equity Shares by the Selling Shareholders
    • Achieve the benefits of listing Equity Shares on the Stock Exchanges

    Mankind Pharma IPO – Basis of Offer Price

    The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.

    Qualitative factors are:

    • Scaled domestic-focused business with potential for further growth;
    • Growing faster than the rate of the IPM with a focus on volume-led growth;
    • Diversified portfolio with market-leading rankings across key therapeutic areas;
    • Established and growing consumer healthcare franchise with brand recall;
    • Leveraged our corporate brand to build and scale brands;
    • Wide market and distribution coverage with a focus on affordability and accessibility;
    • Significant and diversified manufacturing and R&D capabilities; and
    • Experienced and professional management team backed by private equity investors

    Quantitative factors are:

    Basic & Diluted EPS RONW (%) NAV (Rs.)
    31-Mar-22 35.78 23.29 153.65
    31-Mar-21 31.59 26.80
    Mar-20 25.72 29.56

    Mankind Pharma IPO Lead Managers

    Here is the list of Lead managers –

    • Kotak Mahindra Capital Company Limited
    • Axis Capital Limited
    • IIFL Securities Limited
    • Jefferies India Private Limited
    • J.P. Morgan India Private Limited

    Mankind Pharma IPO Registrar to offer

    Check out the details of the registrar here –

    KFin Technologies Limited
    Selenium, Tower B, Plot No. 31 and 32 Financial District, Nanakramguda,
    Serilingampally, Hyderabad, Rangareddi 500 032,
    Telangana, India
    Tel: +91 40 6716 2222
    E-mail: mankind.ipo@kfintech.com
    Website: www.kfintech.com
    Investor Grievance E-mail: einward.ris@kfintech.com
    Contact Person: M Murali Krishna
    SEBI Registration No: INR000000221

    Mankind Pharma IPO – Other Details

    • Statutory Auditor – S.R. Batliboi & Associates LLP, and Goel Gaurav & Co., Chartered Accountants
    • Legal Counsel to the Company – Shardul Amarchand Mangaldas & Co
    • Bankers to the Company – Citi Bank N.A, HDFC Bank Limited, ICICI Bank Limited, and Kotak Mahindra Bank Limited

    Mankind Pharma IPO – Conclusion

    Thus Mankind Pharma, as we know, is a popular, well-known, well-established pharma company having its wings spread in different areas of drug making. The company is now going for a public listing. As we can see through the financial statements, the company’s earnings have grown to a large extent.

    The industry in which Mankind operates is a stable and growing segment. Over the years, the importance of medicines has been enhanced. Therefore, in terms of long-term aspects, Mankind Pharma IPO is a good opportunity for investors.

    To Subscribe to Mankind Pharma IPO – Open Demat Account Now!

      Fill Your Details Here
      1. Open Demat AccountInvest in IPO

      Mankind Pharma IPO Review FAQs

      Check out the FAQs on Mankind Pharma IPO –

      What is the Issue Size of Mankind Pharma IPO?

      The Company is making an initial public offer of 40,058,844 equity shares. They vividly portray the aspects of the issue in this article.

      You can check the stats on the fresh issue, Offer for sale, and net issue.

      What is the Price band of Mankind Pharma IPO?

      The price band for this particular IPO ranges between Rs.1026 to Rs.1080. As far as the face value of the share is of concern, it is Rs.1 per share.

      What is the Mankind Pharma IPO Open Date?

      The opening and closing dates for this IPO have been updated. The IPO is set to open on Apr 25, 2023, while the closing date is set for Apr 27, 2023.

      What is the Mankind Pharma IPO Allotment Date?

      They also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on May 3, 2023, refund initiation is on May 4, 2023, credit of shares is on May 5, 2023, and share listing date is on May 8, 2023.

      What is the Mankind Pharma IPO Listing Date?

      Shares of this company shall be listed in the exchanges on May 8, 2023. The date, when the listing would be done, is stagnant on May 8, 2023.

      Who is the Registrar of Mankind Pharma IPO?

      One of the reputed registrars is managing the issue of this IPO, i.e. KFin Technologies Limited. Their website will help you regarding the further information you are on the lookout for.

      Who is the Promoter of Mankind Pharma IPO?

      Here are the promoters of Mankind Pharma – Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust And Prem Sheetal Family Trust. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.

      What is the GMP of Mankind Pharma IPO?

      They have obtained the GMP of this IPO and it is Rs.100. Further insights into the Kostak rate and subject to sauda or SS are as well included in this report.

      Is Mankind Pharma IPO Good for Investment?

      They have further provided the financial status of the company in this article, from the past few years.

      You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.

      What is the PAT of Mankind Pharma Company?

      They have the information on company financials, and according to that, they have the figures from the last few years to provide.

      The Profit after Tax of Mankind Pharma for the financial year 2022 was Rs. 14,529.56 million. Further, earlier in 2021, and 2020, its PAT stood at Rs. 12,930.34 million, and Rs. 10,561.48 million.

      Featured Topics


      Get 100% IPO Allotment Guarantee! Subscribe to IPO